BUY Aurobindo Pharma — ICICI Securities
byICICI SecuritiesHorizon: NA (inferred Swing (≤2wk))31 Aug 2026via Economic Times New Stock Recos
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Aurobindo stock gains on generic Advair launch
NewsGoogle News·1 Sept · 1w ago
Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD
NewsEt-Markets·31 Aug · 1w ago
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·1 Sept · 1w ago
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.
NSE · Press Release·31 Aug · 2w ago
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus in the US. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in
BSE · Company Update·31 Aug · 2w ago
Aurobindo Pharma arm Apitoria incorporates Avogent Lifesciences as subsidiary
NewsGoogle News·1 Sept · 1w ago
Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.
BSE · Company Update·1 Sept · 1w ago
Aurobindo Pharma’s API plant gets three US FDA observations after inspection
NewsCnbc-Tv18·28 Aug · 2w ago
Here's why these four pharma stocks are in focus today
NewsCnbc-Tv18·24 Aug · 3w ago
USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra
NewsNdtv-Profit·28 Aug · 2w ago
Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA
NewsLivemint·24 Aug · 3w ago
Aurobindo Pharma shares in focus after USFDA closes Raleigh unit inspection with 11 observations
NewsCnbc-Tv18·17 Aug · 4w ago
1 advisor has an active short-term SELL call on this stock
Advisor consensus · adjacent horizon·6 Aug · 1mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Aurobindo Pharma
- SELL — Sahaj Agrawal, Kotak Securities21 Oct 2026 · ~2 weeks · target ₹1,540 · Active
- BUY — Arun Kumar Mantri12 Oct 2026 · ~2 weeks · target ₹1,745 · SL hit
- BUY — Ajit Mishra, Religare12 Oct 2026 · ~2 weeks · target ₹1,820 · SL hit
- BUY — Manas Jaiswal12 Oct 2026 · ~2 weeks · target ₹1,750 · SL hit
- BUY — Rupak De, LKP Securities9 Oct 2026 · ~2 weeks · target ₹1,800 · SL hit
More from ICICI Securities
- BUY CIE Automotive India23 Oct 2026 · ~1 year · target ₹475 · Active
- BUY SAGILITY23 Oct 2026 · ~1 year · target ₹55 · Active
- BUY CREDITACCESS GRAMEEN23 Oct 2026 · ~1 year · target ₹1,500 · Active
- BUY Havells India23 Oct 2026 · ~1 year · target ₹1,500 · Active
- BUY Balkrishna Industries22 Oct 2026 · ~1 year · target ₹2,675 · Active

